Longboard Pharmaceuticals, Inc. (LBPH) Research

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.

Market snapshot

Symbol
LBPH
Price
$59.98
Market cap
$2.3B
P/E ratio
-25.05x
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$61.00

Peer companies

  • BELLUS Health Inc. (BLU)
  • Calliditas Therapeutics AB (publ) (CALT)
  • Deciphera Pharmaceuticals, Inc. (DCPH)
  • DICE Therapeutics, Inc. (DICE)
  • Fusion Pharmaceuticals Inc. (FUSN)
  • Chinook Therapeutics, Inc. (KDNY)
  • MorphoSys AG (MOR)
  • Morphic Holding, Inc. (MORF)

Recent insider activity

  • Lynch Casey — D-Return (22500 shares) on 2024-12-02
  • Lynch Casey — D-Return (14428 shares) on 2024-12-02
  • Lynch Casey — D-Return (12500 shares) on 2024-12-02
  • Lynch Casey — D-Return (12367 shares) on 2024-12-02
  • Le Goff Corinne — D-Return (13397 shares) on 2024-12-02

Open Longboard Pharmaceuticals, Inc. (LBPH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.